Report contributors agreed gammaCore was highly innovative, may be more effective than standard of care alone, and has the potential to save money through the NHS by reducing the cost of treating cluster headache BASKING RIDGE, N.J. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc.,
– Report contributors agreed gammaCore was highly innovative, may be more effective than standard of care alone, and has the potential to save money through the NHS by reducing the cost of treating cluster headache – Basking Ridge, NJ, October 22, 2018 – electroCore, Inc.
BASKING RIDGE, N.J: The UK’s National Institute of Health and Care Excellence (NICE) has published guidance that electroCore’s non-invasive vagus nerve stimulation treatment (gammaCore) for the prevention and acute treatment of migraine and cluster headache is safe and can now be used in the NHS.
The National Institute for Health and Care Excellence (NICE) draft guidance recommends the use of gammaCore for cluster headache in the National Health Service (NHS) LONDON and BASKING RIDGE, N.J. , July 09, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a global commercial-stage
Innovative technology provides patients with convenient, easy-to-use treatment option without the potential side effects associated with commonly prescribed medicines BASKING RIDGE, N.J. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine
Data from Pooled Analysis of ACT1 and ACT2 To Be Presented in Late-Breaking Oral Session at Annual Scientific Meeting of the American Headache Society Basking Ridge, NJ, June 8, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through
ROCKAWAY, N.J. , April 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded Emory University and
electroCore welcomes the recent NIHR technology alert on gammaCore, which profiles the CE-marked device’s role in helping patients in the UK manage long-term neurological conditions such as migraine and medically unexplained symptoms. The alert, which is designed to notify clinicians and those
BASKING RIDGE, N.J. , July 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a global commercial-stage bioelectronic medicine company, today announced data presentations focused on non-invasive vagus nerve stimulation (nVNS) to be presented at the American Headache Society’s 61 st
The Pain & Fatigue Study Center at Mount Sinai Beth Israel in New York has been awarded a United States Army Medical Research grant to conduct a study into the treatment of veterans of the 1990-1991 Gulf War who have Gulf War Illness using electroCore’s non-invasive vagus nerve stimulation (nVNS)